Notice of Redemption of U.S.$1,100,000,000 2.75 per cent

Notice of Redemption of U.S.$1,100,000,000 2.75 per cent. Convertible Bonds due2014 November 26, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")announces that, in accordance with the terms and conditions (the "Conditions")of its U.S.$1,100,000,000 2.75 per cent. convertible bonds due 2014 (ISIN -XS0299687482) (the "Bonds"), the Company has exercised its option underCondition 6(b) to redeem all outstanding Bonds on December 27, 2013 (being theOptional Redemption Date referred to in Condition 6(c)) at par together withinterest accrued to that date. The Company is entitled to exercise this optionunder Condition 6(b)(i) as a result of the Aggregate Value having exceededU.S.$130,000 on each of the 20 dealing days up to and including November 20,2013. An Optional Redemption Notice is today being sent to all Bondholders. As an alternative to the redemption of the Bonds, each Bondholder may exerciseits Conversion Rights in accordance with Condition 5(h). The last day on whichConversion Rights may be exercised by Bondholders is December 13, 2013. TheConversion Period shall end on that date. As at today's date, the Conversion Price is U.S.$32.51 per Ordinary Share. On November 25, 2013, being the latest practicable date prior to the date ofthis announcement, the aggregate principal amount of Bonds outstanding wasU.S.$1,075,070,000 and the closing price of the Ordinary Shares, as derivedfrom the London Stock Exchange, was £28.36. If all Bondholders exercise their Conversion Rights in respect of alloutstanding Bonds, the maximum number of new Ordinary Shares that would beissued in connection with the conversion would be 33,068,902 (representing 5.87per cent. of the current issued share capital of the Company). In accordance with LR 9.6.1 a copy of Optional Redemption Notice sent to allBondholders today has been submitted to the National Storage Mechanism and willbe available for viewing shortly at: www.morningstar.co.uk/uk/nsm. A copy of the Optional Redemption Notice is also available on the Company'swebsite www.shire.com. Words and expressions defined in the Conditions have the same meaning herein. For further information please contact: Investor Relations Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal,Internal Medicine and Regenerative Medicine and we are developing treatmentsfor symptomatic conditions treated by specialist physicians in other targetedtherapeutic areas. www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX